| Literature DB >> 28504206 |
Piti Techavichit1, Darintr Sosothikul1, Thiamjit Chaichana2, Chinachote Teerapakpinyo3, Paul Scott Thorner4, Shanop Shuangshoti5.
Abstract
Juvenile xanthogranuloma (JXG) is a cutaneous form of non-Langerhans cell histiocytosis, primarily affecting children. The lesion is presumed to originate from either macrophages or dermal dendritic cells. JXG can rarely present as an isolated intracranial lesion and, in contrast to the dismal outcome of patients with systemic disease, cranial JXG has been shown to carry a more favorable prognosis. Here, we report for the first time 3 pediatric cases of JXG with a BRAF V600E mutation, 2 with intracranial lesions and 1 with cranial lesions. Although these intracranial/cranial lesions have been referred to as JXG, they likely differ from cutaneous JXG in both the clinical features and BRAF status. It may be more appropriate to classify intracranial/cranial JXG in the same group as Langerhans cell histiocytosis and Erdheim-Chester disease, which also have a BRAF V600E mutation. Further study of BRAF status in a larger series of JXG is warranted.Entities:
Keywords: BRAF; Erdheim-Chester; Histiocytosis; Intracranial; Juvenile xanthogranuloma
Mesh:
Substances:
Year: 2017 PMID: 28504206 DOI: 10.1016/j.humpath.2017.04.026
Source DB: PubMed Journal: Hum Pathol ISSN: 0046-8177 Impact factor: 3.466